|Articles|March 15, 2002
- BioPharm International-03-15-2002
- Volume 15
- Issue 3
Validation of Quantitative PCR Assays?Addressing Virus Contamination Concerns
by Archie Lovatt, Donna McMutrie, John Black, and Iain Doherty Q-One Biotech Ltd. Real-time quantitative PCR has revolutionized the detection and quantification of viral contaminants. Quantitative PCR assays can detect noncytopathic viruses that have recently become a concern in testing for biopharmaceutical safety. High versatility reproducibility, and throughput of such assays decrease the time spent in development, testing, and regulatory compliance.
Advertisement
Articles in this issue
almost 24 years ago
Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?almost 24 years ago
Guest Editorial: Warning Letters ? A Symptom?almost 24 years ago
The Importance of Freezing on Lyophilization Cycle Developmentalmost 24 years ago
Business Benefits of Computer Systems Validationalmost 24 years ago
A System Developer's Approach to ValidationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
2
Next-Generation Modalities Drive New Antibody Discovery
3
How Biopharma Navigates the 2026 Economic Shift
4
Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)
5
